The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk Source: Eur Respir J, 56 (3) 2001919; 10.1183/13993003.01919-2020 Year: 2020
Impact of statins, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARBS) on reducing COPD morbidity Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Impact of statins, angiotensin-converting enzyme inhibitors(ACEI), and angiotensin receptor blockers (ARBs) on reducing COPD morbidity Source: Annual Congress 2010 - COPD: management Year: 2010
Novel inhibitory effect on 5-lipoxygenase activity by montelukast. Evidence for a noncompetitive mode of action Source: Eur Respir J 2004; 24: Suppl. 48, 96s Year: 2004
An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD Source: Eur Respir J, 52 (5) 1801675; 10.1183/13993003.01675-2018 Year: 2018
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
A case control study:The role of leukotriene receptor antagonist in cardiovascular risk Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Association between antacid proton pump inhibitors and histamine 2 receptor antagonists) and incidence of lung cancer: a population-based cohort analysis Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021
Chemopreventive effect of long-term use of low-dose aspirin on lung cancer risk : A nationwide study considering competing risk Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011
Absence of respiratory effects in asthmatic subjects with the If inhibitor ivabradine, a novel anti-anginal agent Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
The combination of PDE4 and PDE5 inhibitors reduces YAP expression in IPF Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018 Year: 2019
Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia Source: Eur Respir J 2008; 31: 611-617 Year: 2008